Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosi
Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- Narrow pulse
- Wide pulse
Results by group
Walking Endurance
Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Narrow Pulse | 42 meters | 60 (Standard Deviation) | 14 |
| Wide Pulse | 25 meters | 35 (Standard Deviation) | 13 |
Narrow Pulse
Wide Pulse
Modified Fatigue Impact Scale
Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Narrow Pulse | 34 score on a scale | 17 (Standard Deviation) | 14 |
| Wide Pulse | 23 score on a scale | 14 (Standard Deviation) | 13 |
Narrow Pulse
Wide Pulse
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Narrow Pulse | 13 | 0 (0.0%) | 0 |
| Wide Pulse | 14 | 0 (0.0%) | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Walking Endurance
Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
Walking and mobilityModified Fatigue Impact Scale
Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
Fatigue
Other measures (1)
Maximal Walking Speed
Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
Walking and mobility
Who could take part
MS (type not specified) · 18 to 55
Show the full criteria
Inclusion criteria
* Able to read, understand, and speak English to ensure safe participation in the project * Difficulties with walking * On stable doses of Ampyra, provigil, or other symptomatic-treating medications * No systemic steroids within the last 30 days * Not currently exercising more than 2x/wk * Able to arrange own transportation to and from the laboratories * Provide informed consent, including willingness to be randomly assigned to one of the two groups
Exclusion criteria
* Documented MS-related relapse in the last 3 months * Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy * Poorly controlled diabetes mellitus or hypertension * History of seizure disorders * Alcohol dependence or abuse (≥2 drinks/day), or present history (last 6 months) of drug abuse * Inability to attend exercise sessions 3 days per week for 6 weeks
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to investigate the capacity of a 6-week treatment with neuromuscular electrical stimulation to improve walking in individuals whose mobility has been compromised by multiple sclerosis.
Papers
Results
Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial.Neurorehabil Neural Repair · 2018
Loading reviews and guidelines…
History
Started
May 2014
Main results due
Dec 2017
Finished
Dec 2017
Results posted
May 2021